Luke D Mitzel1, Peter A Vanable1, Michael P Carey2. 1. Department of Psychology, Syracuse University, Syracuse, New York. 2. Centers for Behavioral and Preventive Medicine, The Miriam Hospital and Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island.
Abstract
BACKGROUND: Stigmatization due to HIV status may interfere with disease management among persons living with HIV (PLWHA) by heightening serostatus disclosure concerns and vulnerability to depressive symptoms. PURPOSE: In this cross-sectional study, indirect effects of disclosure concerns and depressive symptoms were examined for the association of stigma to treatment adherence (medication and clinic appointment adherence) in an outpatient sample of PLWHA. METHOD: Participants (N = 179; 47% White, 41% African-American; 35% MSM) completed measures of stigma-related experiences, concerns about disclosing HIV status, depression, and medication adherence; clinic appointment attendance was obtained from chart data. RESULTS: Stigma had an indirect effect on medication adherence (but not clinic attendance) via disclosure concerns. Stigma had indirect effects on both medication adherence and clinic attendance via depressive symptoms. In path analyses including both disclosure concerns and depressive symptoms, combined indirect effects emerged for both medication adherence and clinic attendance. There was a significant indirect pathway from stigma to disclosure concerns to depression to clinic attendance, whereas the positioning of the mediators was swapped for the significant indirect pathway from stigma to medication adherence. CONCLUSIONS: These analyses provide evidence that stigmatizing experiences negatively affect treatment adherence through the indirect effects of disclosure concerns and depressive symptoms. Disclosure concerns and depressive symptoms are two mechanisms worthy of further research to enhance understanding of the association between stigma and treatment adherence difficulties.
BACKGROUND: Stigmatization due to HIV status may interfere with disease management among persons living with HIV (PLWHA) by heightening serostatus disclosure concerns and vulnerability to depressive symptoms. PURPOSE: In this cross-sectional study, indirect effects of disclosure concerns and depressive symptoms were examined for the association of stigma to treatment adherence (medication and clinic appointment adherence) in an outpatient sample of PLWHA. METHOD: Participants (N = 179; 47% White, 41% African-American; 35% MSM) completed measures of stigma-related experiences, concerns about disclosing HIV status, depression, and medication adherence; clinic appointment attendance was obtained from chart data. RESULTS: Stigma had an indirect effect on medication adherence (but not clinic attendance) via disclosure concerns. Stigma had indirect effects on both medication adherence and clinic attendance via depressive symptoms. In path analyses including both disclosure concerns and depressive symptoms, combined indirect effects emerged for both medication adherence and clinic attendance. There was a significant indirect pathway from stigma to disclosure concerns to depression to clinic attendance, whereas the positioning of the mediators was swapped for the significant indirect pathway from stigma to medication adherence. CONCLUSIONS: These analyses provide evidence that stigmatizing experiences negatively affect treatment adherence through the indirect effects of disclosure concerns and depressive symptoms. Disclosure concerns and depressive symptoms are two mechanisms worthy of further research to enhance understanding of the association between stigma and treatment adherence difficulties.
Entities:
Keywords:
HIV stigma; adherence; depressive symptoms; disclosure concerns
Authors: Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2004-03-01 Impact factor: 3.731
Authors: Stephenie R Chaudoir; Wynne E Norton; Valerie A Earnshaw; Linda Moneyham; Michael J Mugavero; Kathie M Hiers Journal: AIDS Behav Date: 2012-11
Authors: Edward M Gardner; Katherine H Hullsiek; Edward E Telzak; Shweta Sharma; Grace Peng; William J Burman; Rodger D MacArthur; Margaret Chesney; Gerald Friedland; Sharon B Mannheimer Journal: AIDS Date: 2010-01-28 Impact factor: 4.177
Authors: Wayne T Steward; Gregory M Herek; Jayashree Ramakrishna; Shalini Bharat; Sara Chandy; Judith Wrubel; Maria L Ekstrand Journal: Soc Sci Med Date: 2008-07-01 Impact factor: 4.634
Authors: Bulent Turan; Whitney Smith; Mardge H Cohen; Tracey E Wilson; Adaora A Adimora; Daniel Merenstein; Adebola Adedimeji; Eryka L Wentz; Antonina G Foster; Lisa Metsch; Phyllis C Tien; Sheri D Weiser; Janet M Turan Journal: J Acquir Immune Defic Syndr Date: 2016-06-01 Impact factor: 3.731
Authors: Ann-Margaret Dunn Navarra; Robin Whittemore; Suzanne Bakken; Michael J Rosenberg; Maurade Gormley; John Bethea; Marya Gwadz; Charles Cleland; Eva Liang; Gail D'Eramo Melkus Journal: Nurs Res Date: 2020 May/Jun Impact factor: 2.381
Authors: Andrey Oeiras Pedroso; Dulce Gomes; Sara Melissa Lago Sousa; Glenda Roberta Oliveira Naiff Ferreira; Aline Maria Pereira Cruz Ramos; Sandra Helena Isse Polaro; Laura Maria Vidal Nogueira; Eliã Pinheiro Botelho Journal: Trop Med Infect Dis Date: 2022-07-16
Authors: Flavio Mandlate; M Claire Greene; Luis F Pereira; Annika C Sweetland; Donald Kokonya; Cristiane S Duarte; Francine Cournos; Maria A Oquendo; Milton L Wainberg; Mohsin Sidat; Esperança Sevene; Marcelo F Mello Journal: Front Public Health Date: 2022-09-28